Edith Heard chosen as new EMBL director
Edith Heard, member of both EpiGeneSys and EpiGene2Sys, has been elected unanimously as the new director of EMBL.
Edith Heard studied Natural Sciences at Cambridge University and then moved to “Imperial Cancer Research Fund” in London to do a PhD in cancer research. Her studies made her realise that in order to understand the cancer cell, one must first understand the normal cell and embryogenesis. After joining Philip Avner's laboratory at the Institut Pasteur in 2001 she joined the ATIP team “Epigenesys and mammarian development” at Institut Curie in the unit headed by Geneviève Almouzni. In 2008, she was made director of the Genetics and Developmental Biology department at Institut Curie, where she continues her research on the inactivation of the X chromosome. Heard was selected as a Fellow of the Royal Society in 2013 in recognition for her ground-breaking discoveries in epigenetics. She was elected as Professor at the Collège de France in 2012 and has received numerous awards and prizes.
She will start her mandate at the EMBL on 1st January 2019.
A tribute from Geneviève Almouzni:
My colleague and friend Edith Heard will be taking the position of director of the EMBL starting in 2019. This is a wonderful choice, and an honor for the Institut Curie to contribute with a wonderful member of our community to the future of a key European Organization. As always, I will be happy to work with her for a successful transition. I am pleased that we will be able to build on this for the future!